158 related articles for article (PubMed ID: 16546964)
1. Novel missense mutation of the DNA topoisomerase I gene in SN-38-resistant DLD-1 cells.
Arakawa Y; Suzuki H; Saito S; Yamada H
Mol Cancer Ther; 2006 Mar; 5(3):502-8. PubMed ID: 16546964
[TBL] [Abstract][Full Text] [Related]
2. Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Jensen NF; Agama K; Roy A; Smith DH; Pfister TD; Rømer MU; Zhang HL; Doroshow JH; Knudsen BR; Stenvang J; Brünner N; Pommier Y
J Exp Clin Cancer Res; 2016 Mar; 35():56. PubMed ID: 27029323
[TBL] [Abstract][Full Text] [Related]
3. Three missense mutations of DNA topoisomerase I in highly camptothecin-resistant colon cancer cell sublines.
Arakawa Y; Ozaki K; Okawa Y; Yamada H
Oncol Rep; 2013 Sep; 30(3):1053-8. PubMed ID: 23836376
[TBL] [Abstract][Full Text] [Related]
4. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance.
Wang LF; Ting CY; Lo CK; Su JS; Mickley LA; Fojo AT; Whang-Peng J; Hwang J
Cancer Res; 1997 Apr; 57(8):1516-22. PubMed ID: 9108454
[TBL] [Abstract][Full Text] [Related]
5. Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Urasaki Y; Laco GS; Pourquier P; Takebayashi Y; Kohlhagen G; Gioffre C; Zhang H; Chatterjee D; Pantazis P; Pommier Y
Cancer Res; 2001 Mar; 61(5):1964-9. PubMed ID: 11280753
[TBL] [Abstract][Full Text] [Related]
6. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant.
Joto N; Ishii M; Minami M; Kuga H; Mitsui I; Tohgo A
Int J Cancer; 1997 Aug; 72(4):680-6. PubMed ID: 9259410
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of the camptothecin resistance of Glu710Gly topoisomerase IB mutant analyzed in vitro and in silico.
Tesauro C; Morozzo della Rocca B; Ottaviani A; Coletta A; Zuccaro L; Arnò B; D'Annessa I; Fiorani P; Desideri A
Mol Cancer; 2013 Sep; 12(1):100. PubMed ID: 24004603
[TBL] [Abstract][Full Text] [Related]
8. New Topoisomerase I mutations are associated with resistance to camptothecin.
Gongora C; Vezzio-Vie N; Tuduri S; Denis V; Causse A; Auzanneau C; Collod-Beroud G; Coquelle A; Pasero P; Pourquier P; Martineau P; Del Rio M
Mol Cancer; 2011 May; 10():64. PubMed ID: 21619602
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of resistance in a human cell line exposed to sequential topoisomerase poisoning.
Saleem A; Ibrahim N; Patel M; Li XG; Gupta E; Mendoza J; Pantazis P; Rubin EH
Cancer Res; 1997 Nov; 57(22):5100-6. PubMed ID: 9371509
[TBL] [Abstract][Full Text] [Related]
10. Establishment of a 7-ethyl-10-hydroxy-camptothecin-resistant small cell lung cancer cell line.
Chikamori M; Takigawa N; Kiura K; Tabata M; Shibayama T; Segawa Y; Ueoka H; Ohnoshi T; Tanimoto M
Anticancer Res; 2004; 24(6):3911-6. PubMed ID: 15736431
[TBL] [Abstract][Full Text] [Related]
11. Acquired irinotecan resistance is accompanied by stable modifications of cell cycle dynamics independent of MSI status.
Petitprez A; Poindessous V; Ouaret D; Regairaz M; Bastian G; Guérin E; Escargueil AE; Larsen AK
Int J Oncol; 2013 May; 42(5):1644-53. PubMed ID: 23546019
[TBL] [Abstract][Full Text] [Related]
12. Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Yanase K; Sugimoto Y; Andoh T; Tsuruo T
Int J Cancer; 1999 Mar; 81(1):134-40. PubMed ID: 10077164
[TBL] [Abstract][Full Text] [Related]
13. The human DNA topoisomerase I mutant Gly717Asp: Higher religation rate is not always associated with camptothecin resistance.
Wang Z; D'Annessa I; Tesauro C; Ottaviani A; Soren BC; Dasari JB; Messina B; Thareparambil A; Fiorani P
Arch Biochem Biophys; 2019 Mar; 663():165-172. PubMed ID: 30653963
[TBL] [Abstract][Full Text] [Related]
14. CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2012; 7(11):e50427. PubMed ID: 23185622
[TBL] [Abstract][Full Text] [Related]
15. CPT-11 in human colon-cancer cell lines and xenografts: characterization of cellular sensitivity determinants.
Jansen WJ; Zwart B; Hulscher ST; Giaccone G; Pinedo HM; Boven E
Int J Cancer; 1997 Jan; 70(3):335-40. PubMed ID: 9033637
[TBL] [Abstract][Full Text] [Related]
16. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
[TBL] [Abstract][Full Text] [Related]
17. Establishment and characterization of human gastric and colonic xenograft lines resistant to CPT-11 (a new derivative of camptothecin).
Nagai S; Yamauchi M; Andoh T; Nishizawa M; Satta T; Kodera Y; Kondou K; Akiyama S; Ito K; Takagi H
J Surg Oncol; 1995 Jun; 59(2):116-24. PubMed ID: 7776652
[TBL] [Abstract][Full Text] [Related]
18. 7-Ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy camptothecin: mechanism of resistance and clinical trials.
Saijo N; Nishio K; Kubota N; Kanzawa F; Shinkai T; Karato A; Sasaki Y; Eguchi K; Tamura T; Ohe Y
Cancer Chemother Pharmacol; 1994; 34 Suppl():S112-7. PubMed ID: 8070019
[TBL] [Abstract][Full Text] [Related]
19. Heterozygous disruption of the DNA topoisomerase I gene confers cellular resistance to camptothecin in human cells.
Toyoda E; Kurosawa A; Fujii M; Adachi N
Biol Pharm Bull; 2009 Apr; 32(4):724-7. PubMed ID: 19336913
[TBL] [Abstract][Full Text] [Related]
20. Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
McDonald AC; Brown R
Br J Cancer; 1998 Sep; 78(6):745-51. PubMed ID: 9743293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
